Phase 2 RCT: Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer.

Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial – The Lancet Oncology

Commentary on Twitter

In the phase II NEOBLADE trial in 120 pts with locally advanced MIBC, addition of the multitarget RTK TKI nindetanib to neoadjuvant chemotherapy did not significantly improve the pCR rate: 37% versus 32% (OR 1.25, 70% CI 0.84–1.87; P=0.28): https://t.co/m9NXouhOcZ #blcsm

— NatureRevClinOncol (@NatRevClinOncol) April 22, 2022